欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (12): 1701-1710.doi: 10.12092/j.issn.1009-2501.2025.12.014

• 综述与讲座 • 上一篇    下一篇

GLP-1受体激动剂治疗糖尿病肾病作用机制的研究进展

黄淑敏1,2,谢保城2,刘国辉1,2   

  1. 1广东医科大学第一临床医学院,湛江  524000,广东;2南方医科大学第十附属医院(东莞市人民医院),东莞  523000,广东

  • 收稿日期:2024-10-08 修回日期:2025-02-21 出版日期:2025-12-26 发布日期:1900-01-01
  • 通讯作者: 刘国辉,通信作者,男,主任医师,研究生导师,研究方向:肾脏内科。 E-mail: Liuguohui5@126.com
  • 作者简介:黄淑敏,女,研究生在读,研究方向:肾脏内科。 E-mail: 1179403842@qq.com
  • 基金资助:
    广东省医学科研基金(A2024138);广东省医院药师青年托举研究基金(2023QNTJ39)

Research progress on the mechanism of GLP-1 receptor agonists in the treatment of diabetic nephropathy

HUANG Shumin1,2, XIE Baocheng2, LIU Guohui1,2   

  1. 1 The First Clinical School of Medicine, Guangdong Medical University, Zhanjiang 524000, Guangdong, China; 2The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan 523000, Guangdong, China
  • Received:2024-10-08 Revised:2025-02-21 Online:2025-12-26 Published:1900-01-01

摘要:

糖尿病肾病(diabetic nephropathy,DN)是全球终末期肾病(end-stage renal disease,ESRD)的主要病因。近年来,新型降糖药物胰高血糖素样肽-1 (glucagon-like peptide-1,GLP-1)受体激动剂获得广泛关注。研究发现其通过减轻炎症反应、抑制氧化应激、抗纤维化、改善肾脏血流动力学、调节脂质代谢紊乱、影响细胞程序性死亡等多种机制在治疗糖尿病肾病研究领域有着广阔前景。本文就GLP-1受体激动剂的生物学功能及其治疗糖尿病肾病的作用机制进行综述。

关键词: GLP-1受体激动剂, 糖尿病肾病, 作用机制, 研究进展

Abstract:

Diabetic nephropathy (DN) remains the leading cause of end-stage renal disease (ESRD) worldwide. In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists, a novel class of hypoglycemic agents, have garnered significant attention in the field of diabetology. Emerging evidence suggests these therapeutic agents demonstrate considerable potential in diabetic nephropathy management through multiple pathways, including inflammation modulation, oxidative stress reduction, anti-fibrotic effects, renal hemodynamic improvement, lipid metabolism regulation, and modulation of programmed cell death pathways. This comprehensive review examines the pleiotropic biological functions of GLP-1 receptor agonists and elucidates their multifaceted mechanisms of action in combating diabetic nephropathy progression.

Key words: GLP-1 receptor agonists, diabetic nephropathy, mechanism of action, research progress

中图分类号: